BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, April 28, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Gilead investor sentiment remains flat amid continued focus on next steps

Feb. 5, 2020
By Michael Fitzhugh
Modest revenue growth and a 2020 outlook that left analysts uninspired about its near-term prospects pushed Gilead Sciences Inc. shares (NASDAQ:GILD) down about 2% to close Feb. 5 at $65.87, despite growing sales of its HIV medicine, Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide), and what CEO Daniel O'Day called "a sense of urgency" around further business development.
Read More

Regulatory front for Feb. 5, 2020

Feb. 5, 2020
The latest global regulatory news, changes and updates affecting biopharma, including: Raregen, Sandoz, United.
Read More
Coronavirus microscopic model
Ebola, malaria, HIV, TCM

Researchers cast wide net for rapid-draw weapons in 2019-nCoV fight

Feb. 4, 2020
By Anette Breindl
At this very early point in the emerging 2019-nCoV outbreak, knowledge about the virus is insufficient to predict what shape that outbreak will ultimately take. But knowledge about the virus is accumulating at remarkable speed, and experience with other viruses is helping to shape the response to the newest coronavirus threat. 2019-nCoV, sometimes called Wuhan coronavirus after its source, is the third coronavirus after SARS-CoV and MERS-CoV with the potential to cause serious illness and death that has emerged since the beginning of the 21st century.
Read More

Preventing a U.S. outbreak: Emergency declaration leads to hunt for more funding

Feb. 4, 2020
By Mari Serebrov
Now that U.S. Health and Human Services (HHS) Secretary Alex Azar has declared a nationwide public health emergency due to the 2019 novel coronavirus (2019-nCoV), HHS is saying it may need more money to help it be as proactive and aggressive as possible in detecting the virus and containing an outbreak.
Read More
Traditional Chinese medicine illustration

Coronavirus: Chinese researchers claim TCM herbal remedy could ‘inhibit’ 2019-nCoV

Feb. 4, 2020
By Cornelia Zou
HONG KONG – In another example that communication is proving as difficult as containment in the current coronavirus outbreak, China’s state media reported, to increasing skepticism, that a traditional Chinese medicine (TCM) oral liquid could inhibit the new coronavirus.
Read More

Other news to note for Feb. 4, 2020

Feb. 4, 2020
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Advaccine, Anticancer, Asahi Kasei, Aspen, Avacta, BGI, Biolexis, Celularity, Clover, Curetis, Curevac, Daewoong, Duke-National University, Horizon, Inovio, Novartis, Outlook, Oxford Gene Technology, Sandoz, Sorrento, Sysmex, Takeda, Veloxis, Wuhan Institute of Virology, Wuxi Biologics.
Read More

Regulatory front for Feb. 4, 2020

Feb. 4, 2020
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: GE Healthcare.
Read More

Other news to note for Feb. 4, 2020

Feb. 4, 2020
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aevi Genomics, Anika, Anteros, Athenex, Arthrosurface, Beijing CC-Pharming, Biomotiv, Biosense Webster, BMS, Boehringer, Cerecor, Contrafect, Cormedix, CNS Pharmaceuticals, Equinox, Eyepoint, FSD, Genekam, Ibio, Inprother, Levena, Mablytics, Navrogen, Pattern Bioscience, Plex, Porton Pharma, Q Biomed, Rhythm AI, Salarius, Samus, Sirion, Solarvest, Syntrix, Theratechnologies, Trefoil, Trianni.
Read More
2-3-Azar-HHS.png

HHS declares public health emergency in part because CDC test for coronavirus unreliable

Feb. 3, 2020
By Mark McCarty
The U.S. Department of Health and Human Services has declared a public health emergency in the U.S. over the coronavirus in part because a government diagnostic for the virus yields inconsistent results, a fact that may spur the life sciences to provide a solution.
Read More
2-3-Novacyt-primerdesign-genesig-16.png

Novacyt launches test for new coronavirus

Feb. 3, 2020
By Meg Bryant
As the deadly coronavirus continues to spread, countries around the world are scrambling to understand the public health threat and identify and quarantine people who may be infected. To that end, Novacyt SA has launched a molecular test that detects only the 2019 strain of the coronavirus, reducing the chance of false diagnoses.
Read More
Previous 1 2 … 530 531 532 533 534 535 536 537 538 … 552 553 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 28, 2026.
  • Illustration of a tumor

    Detecting the invisible: minimal residual disease at AACR 2026

    BioWorld Science
    Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 28, 2026
  • Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists

    BioWorld Science
    Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
  • Cerebral aneurysm illustration

    Grace Therapeutics hits CRL setback with GTx-104 despite positive trial

    BioWorld
    Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing